Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus

J Am Acad Dermatol. 2019 Jul;81(1):23-41. doi: 10.1016/j.jaad.2018.10.072. Epub 2018 Nov 29.

Abstract

In 1964, the first human oncovirus, Epstein-Barr virus, was identified in Burkitt lymphoma cells. Since then, 6 other human oncoviruses have been identified: human papillomavirus, Merkel cell polyomavirus, hepatitis B and C viruses, human T-cell lymphotropic virus-1, and human herpesvirus-8. These viruses are causally linked to 12% of all cancers, many of which have mucocutaneous manifestations. In addition, oncoviruses are associated with multiple benign mucocutaneous diseases. Research regarding the pathogenic mechanisms of oncoviruses and virus-specific treatment and prevention is rapidly evolving. Preventative vaccines for human papillomavirus and hepatitis B virus are already available. This review discusses the mucocutaneous manifestations, pathogenesis, diagnosis, treatment, and prevention of oncovirus-related diseases. The first article in this continuing medical education series focuses on diseases associated with human papillomavirus and Merkel cell polyomavirus, while the second article in the series focuses on diseases associated with hepatitis B and C viruses, human T-cell lymphotropic virus-1, human herpesvirus-8, and Epstein-Barr virus.

Keywords: Epstein–Barr virus; Kaposi sarcoma; adult T-cell leukemia/lymphoma; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; human T-cell lymphotropic virus-1; human herpesvirus-8; oncovirus.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Deltaretrovirus / isolation & purification
  • Deltaretrovirus / pathogenicity*
  • Education, Medical, Continuing
  • Female
  • Hepatitis Viruses / isolation & purification
  • Hepatitis Viruses / pathogenicity
  • Herpesviridae / isolation & purification
  • Herpesviridae / pathogenicity*
  • Herpesvirus 4, Human / isolation & purification
  • Herpesvirus 4, Human / pathogenicity
  • Humans
  • Male
  • Primary Prevention
  • Prognosis
  • Retroviridae / isolation & purification
  • Retroviridae / pathogenicity*
  • Risk Assessment
  • Skin Neoplasms / epidemiology
  • Skin Neoplasms / physiopathology
  • Skin Neoplasms / therapy
  • Skin Neoplasms / virology*
  • Survival Analysis
  • Tumor Virus Infections / epidemiology*
  • Tumor Virus Infections / physiopathology
  • Tumor Virus Infections / therapy
  • Tumor Virus Infections / virology*